GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of £38billion.

The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on ...

Bearish flow noted in GSK (GSK) Pharma with 1,694 puts trading, or 4x expected. Most active are 2/7 weekly 34 puts and Jan-27 28 puts, with total volume in those strikes near 1,600 contracts. The ...

Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and ...

Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.